MY195680A - 1,3,4-Thiadiazole Compounds and their use in Treating Cancer - Google Patents

1,3,4-Thiadiazole Compounds and their use in Treating Cancer

Info

Publication number
MY195680A
MY195680A MYPI2018702070A MYPI2018702070A MY195680A MY 195680 A MY195680 A MY 195680A MY PI2018702070 A MYPI2018702070 A MY PI2018702070A MY PI2018702070 A MYPI2018702070 A MY PI2018702070A MY 195680 A MY195680 A MY 195680A
Authority
MY
Malaysia
Prior art keywords
treating cancer
thiadiazole compounds
compound
formula
taken together
Prior art date
Application number
MYPI2018702070A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
David Robert Perkins
Johannes Wilhelmus Maria Nissink
Piotr Antoni Raubo
Peter Duncan Smith
Andrew Bailey
Original Assignee
Cancer Research Tech Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd, Astrazeneca Ab filed Critical Cancer Research Tech Ltd
Publication of MY195680A publication Critical patent/MY195680A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2018702070A 2015-11-30 2016-11-30 1,3,4-Thiadiazole Compounds and their use in Treating Cancer MY195680A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260784P 2015-11-30 2015-11-30
PCT/EP2016/079253 WO2017093301A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
MY195680A true MY195680A (en) 2023-02-03

Family

ID=57460503

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018702070A MY195680A (en) 2015-11-30 2016-11-30 1,3,4-Thiadiazole Compounds and their use in Treating Cancer

Country Status (28)

Country Link
US (1) US10040789B2 (de)
EP (1) EP3383872B1 (de)
JP (1) JP6821680B2 (de)
KR (1) KR20180083411A (de)
CN (1) CN108349965B (de)
AR (1) AR106875A1 (de)
AU (1) AU2016361834B2 (de)
BR (1) BR112018008330B1 (de)
CA (1) CA3005517C (de)
CL (1) CL2018001409A1 (de)
CO (1) CO2018006930A2 (de)
DK (1) DK3383872T3 (de)
DO (1) DOP2018000135A (de)
EA (1) EA035519B9 (de)
ES (1) ES2796562T3 (de)
IL (1) IL259508A (de)
MX (1) MX2018006483A (de)
MY (1) MY195680A (de)
NI (1) NI201800063A (de)
NZ (1) NZ743699A (de)
PE (1) PE20181522A1 (de)
PH (1) PH12018501133A1 (de)
SG (1) SG11201803808VA (de)
SV (1) SV2018005700A (de)
TN (1) TN2018000118A1 (de)
TW (1) TW201731511A (de)
WO (1) WO2017093301A1 (de)
ZA (1) ZA201804361B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201730188A (zh) 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
WO2020078350A1 (zh) * 2018-10-16 2020-04-23 南京明德新药研发有限公司 噻二唑衍生物及其作为gls1抑制剂的应用
CN114560855B (zh) * 2021-03-26 2023-05-23 成都苑东生物制药股份有限公司 环烷基甲酰胺类衍生物、其制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761866T3 (es) 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
JP6783663B2 (ja) 2014-01-06 2020-11-11 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
AU2016361834A1 (en) 2018-07-12
US20170333429A1 (en) 2017-11-23
MX2018006483A (es) 2019-08-12
AR106875A1 (es) 2018-02-28
JP2018535235A (ja) 2018-11-29
TN2018000118A1 (en) 2019-10-04
EP3383872A1 (de) 2018-10-10
KR20180083411A (ko) 2018-07-20
DK3383872T3 (da) 2020-06-08
CO2018006930A2 (es) 2018-10-10
CA3005517A1 (en) 2017-06-08
SV2018005700A (es) 2019-03-07
WO2017093301A1 (en) 2017-06-08
EA035519B1 (ru) 2020-06-29
NZ743699A (en) 2023-02-24
CN108349965A (zh) 2018-07-31
BR112018008330B1 (pt) 2023-03-07
JP6821680B2 (ja) 2021-01-27
US10040789B2 (en) 2018-08-07
TW201731511A (zh) 2017-09-16
DOP2018000135A (es) 2018-06-30
CN108349965B (zh) 2021-10-26
SG11201803808VA (en) 2018-06-28
EA201891239A1 (ru) 2018-11-30
CA3005517C (en) 2023-12-12
IL259508A (en) 2018-07-31
PE20181522A1 (es) 2018-09-24
PH12018501133A1 (en) 2019-01-21
EP3383872B1 (de) 2020-05-20
EA035519B9 (ru) 2020-08-10
CL2018001409A1 (es) 2018-12-07
ES2796562T3 (es) 2020-11-27
AU2016361834B2 (en) 2019-11-14
ZA201804361B (en) 2019-07-31
NI201800063A (es) 2018-10-18
BR112018008330A2 (pt) 2018-10-30

Similar Documents

Publication Publication Date Title
PH12018501133A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MX2020010737A (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2015011229A (es) Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
MX2015014033A (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX2018004664A (es) Antagonistas de ep4.
PH12020552261A1 (en) Proteasome activity enhancing compounds
PH12017500159A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
PH12018501131A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MX2021001612A (es) Compuestos utiles en terapia del vih.
GEP20186893B (en) Pyrazines modulators of gpr6
PH12018501132A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2021003481A (es) Compuesto heterociclico.